vs
Side-by-side financial comparison of Apyx Medical Corp (APYX) and Commercial Bancgroup, Inc. (CBK). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $19.2M, roughly 1.2× Apyx Medical Corp). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -6.8%, a 48.1% gap on every dollar of revenue.
Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
APYX vs CBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $19.2M | $23.1M |
| Net Profit | $-1.3M | $9.5M |
| Gross Margin | 62.6% | — |
| Operating Margin | 0.1% | — |
| Net Margin | -6.8% | 41.3% |
| Revenue YoY | 34.7% | — |
| Net Profit YoY | 71.9% | 9.7% |
| EPS (diluted) | — | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $23.1M | ||
| Q4 25 | $19.2M | $23.5M | ||
| Q3 25 | $12.9M | $22.8M | ||
| Q2 25 | $11.4M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $14.2M | — | ||
| Q3 24 | $11.5M | — | ||
| Q2 24 | $12.1M | — |
| Q1 26 | — | $9.5M | ||
| Q4 25 | $-1.3M | $9.9M | ||
| Q3 25 | $-2.0M | $9.5M | ||
| Q2 25 | $-3.8M | — | ||
| Q1 25 | $-4.2M | — | ||
| Q4 24 | $-4.6M | — | ||
| Q3 24 | $-4.7M | — | ||
| Q2 24 | $-6.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 62.6% | — | ||
| Q3 25 | 64.4% | — | ||
| Q2 25 | 62.3% | — | ||
| Q1 25 | 60.1% | — | ||
| Q4 24 | 63.0% | — | ||
| Q3 24 | 60.5% | — | ||
| Q2 24 | 61.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | -6.5% | 53.8% | ||
| Q2 25 | -22.6% | — | ||
| Q1 25 | -32.4% | — | ||
| Q4 24 | -21.4% | — | ||
| Q3 24 | -31.6% | — | ||
| Q2 24 | -45.7% | — |
| Q1 26 | — | 41.3% | ||
| Q4 25 | -6.8% | 42.2% | ||
| Q3 25 | -15.4% | 41.4% | ||
| Q2 25 | -33.2% | — | ||
| Q1 25 | -44.0% | — | ||
| Q4 24 | -32.5% | — | ||
| Q3 24 | -40.9% | — | ||
| Q2 24 | -54.0% | — |
| Q1 26 | — | $0.69 | ||
| Q4 25 | — | $0.72 | ||
| Q3 25 | — | $0.77 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $31.7M | — |
| Total DebtLower is stronger | $37.5M | $118.2M |
| Stockholders' EquityBook value | $14.5M | — |
| Total Assets | $66.8M | $2.3B |
| Debt / EquityLower = less leverage | 2.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $31.7M | — | ||
| Q3 25 | $25.1M | $154.8M | ||
| Q2 25 | $29.3M | — | ||
| Q1 25 | $31.0M | — | ||
| Q4 24 | $31.7M | — | ||
| Q3 24 | $28.0M | — | ||
| Q2 24 | $32.7M | — |
| Q1 26 | — | $118.2M | ||
| Q4 25 | $37.5M | $166.8M | ||
| Q3 25 | $37.5M | $100.1M | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $14.5M | — | ||
| Q3 25 | $5.8M | $245.2M | ||
| Q2 25 | $7.3M | — | ||
| Q1 25 | $10.5M | — | ||
| Q4 24 | $14.2M | — | ||
| Q3 24 | $11.0M | — | ||
| Q2 24 | $14.7M | — |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $66.8M | $2.3B | ||
| Q3 25 | $57.4M | $2.2B | ||
| Q2 25 | $58.2M | — | ||
| Q1 25 | $60.2M | — | ||
| Q4 24 | $64.8M | — | ||
| Q3 24 | $60.7M | — | ||
| Q2 24 | $65.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | 0.41× | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.5M | — |
| Free Cash FlowOCF − Capex | $-2.8M | — |
| FCF MarginFCF / Revenue | -14.6% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-2.5M | — | ||
| Q3 25 | $-3.5M | $28.0M | ||
| Q2 25 | $-1.2M | — | ||
| Q1 25 | $-702.0K | — | ||
| Q4 24 | $-2.9M | — | ||
| Q3 24 | $-4.4M | — | ||
| Q2 24 | $-4.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-4.1M | $26.5M | ||
| Q2 25 | $-1.5M | — | ||
| Q1 25 | $-757.0K | — | ||
| Q4 24 | $-3.2M | — | ||
| Q3 24 | $-4.6M | — | ||
| Q2 24 | $-4.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -31.5% | 115.8% | ||
| Q2 25 | -13.2% | — | ||
| Q1 25 | -8.0% | — | ||
| Q4 24 | -22.4% | — | ||
| Q3 24 | -40.0% | — | ||
| Q2 24 | -38.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 4.0% | 6.7% | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 1.7% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 2.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.96× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APYX
Segment breakdown not available.
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
